We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

19 hedge funds and large institutions have $2.78M invested in Aprea Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

6% more funds holding

Funds holding: 18 → 19 (+1)

0.9% more ownership

Funds ownership: 22.74% → 23.64% (+0.9%)

26% less capital invested

Capital invested by funds: $3.77M → $2.78M (-$993K)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
1
Closed
2
Calls
$416K
Puts
–
Net Calls
+$416K
Net Calls Change
-$199K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$87.9K
2
ACM
AIGH Capital Management
Maryland
+$16K
3
WVP
Worth Venture Partners
New Jersey
+$8.57K
4
TRCT
Tower Research Capital (TRC)
New York
+$6.89K
5
MLA
MB, Levis & Associates
Pennsylvania
+$3K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2.5K
2
Bank of America
Bank of America
North Carolina
-$44
3
QC
Quent Capital
New York
-$13
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.1M +$16K +4,300 +1%
SCM
2
Sio Capital Management
New York
$882K – – –
Walleye Capital
3
Walleye Capital
New York
$295K +$1.36K +364 +0.4%
WVP
4
Worth Venture Partners
New Jersey
$275K +$8.57K +2,300 +3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$74.3K +$87.9K +23,590 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$48.8K – – –
Morgan Stanley
7
Morgan Stanley
New York
$48.1K +$2.73K +733 +5%
BlackRock
8
BlackRock
New York
$29.1K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$10.5K +$6.89K +1,848 +125%
Group One Trading
10
Group One Trading
Illinois
$6.8K – – –
PNC Financial Services Group
11
PNC Financial Services Group
Pennsylvania
$3.15K – – –
MLA
12
MB, Levis & Associates
Pennsylvania
$2.54K +$3K +806 New
Wells Fargo
13
Wells Fargo
California
$860 +$34 +9 +3%
Osaic Holdings
14
Osaic Holdings
Arizona
$630 – – –
PGAM
15
Princeton Global Asset Management
New Jersey
$315 – – –
Northwestern Mutual Wealth Management
16
Northwestern Mutual Wealth Management
Wisconsin
$148 +$175 +47 New
KTC
17
Kistler-Tiffany Companies
Pennsylvania
$79 – – –
UBS Group
18
UBS Group
Switzerland
$9 -$2.5K -671 -100%
Bank of America
19
Bank of America
North Carolina
– -$44 -10 Closed
QC
20
Quent Capital
New York
– -$13 -3 Closed
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
– +$373 +100 +435%

APRE Hedge Fund Activity: Q2 2023 in Review

19 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2023, worth a combined $2.78M — down 26% from $3.77M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new APRE positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $87.9K. The largest seller was UBS Group, cutting an estimated $2.5K.

  • 19 institutional investors held Aprea Therapeutics (APRE) as of Q2 2023, up from 18 in Q1 2023.
  • Funds reported $2.78M of Aprea Therapeutics stock for Q2 2023, down 26% quarter-over-quarter.
  • 3 funds opened new Aprea Therapeutics positions in Q2 2023 and 2 closed out, a net change of +1 holder.
  • The largest Aprea Therapeutics buyer in Q2 2023 was Geode Capital Management, an estimated $87.9K added.
  • The largest Aprea Therapeutics seller in Q2 2023 was UBS Group, an estimated $2.5K sold.

Based on aggregated 13F filings for Q2 2023.